Steglatro sales have never been better. It is now 2nd in new scripts behind Jardiance but BI is having virtual meetings with their sales reps because Steglatro has gained so much share. This drug will easily replace Januvia as Merck’s diabetic drug which makes a big difference in the market and more importantly Merck’s bottom line. If all Merck’s drugs had performed like Steglatro Merck could have gave a rosier picture to investors.How is it doing in sales?